Navigation Links
Genomic Health Announces Management Changes and New Responsibilities
Date:1/8/2009

located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the ability of the company to continue its efforts to expand worldwide commercialization of the Oncotype DX breast cancer assay, to advance its research and development pipeline and to move the company toward profitability, and the company's belief that Mr. Cole's appointment as COO further strengthens the company's ability to deliver its services to patients and physicians around the world. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: the results of additional clinical studies; the applicability of clinical study results to actual outcomes; the risk that we may not obtain or maintain sufficient levels of reimbursement for our test; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to develop new tests; unanticipated costs or delays in research and development efforts; our ability to continue to narrow our net loss; our ability to obtain capital when needed; our history of operating losses and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the three-month period ended September 30, 2008. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service mark
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Nutrigenomics - Developing Personalized Diets for Disease Prevention - Is the Focus of a Special Issue of OMICS
2. Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors
3. Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology
4. Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
6. UC San Diego to lead nationwide program in pharmacogenomics
7. NeoGenomics to Present at the Noble Financial Equity Conference
8. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
9. Genomic Health to Announce Second Quarter 2008 Financial Results and Host Conference Call on Tuesday, August 5, 2008
10. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
11. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3Hospital infections cost 241 billion in lost bed days 56007 1Hospital infections cost 241 billion in lost bed days 56007 2Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 1Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 2Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 3Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 4BioMarin to Present at the Baird Healthcare Conference 13799 1BioMarin to Present at the Baird Healthcare Conference 13799 2
Other Medicine Technology:Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress 2Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 2Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 4Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 5Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 6Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 8Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 9